600079 ST人福
已收盘 10-22 15:00:00
资讯
新帖
简况
股市必读:ST人福新发布《关于芦比前列酮软胶囊获得美国FDA批准文号的公告》
证券之星 · 10-21 01:17
股市必读:ST人福新发布《关于芦比前列酮软胶囊获得美国FDA批准文号的公告》
ST人福(600079.SH):芦比前列酮软胶囊获得美国FDA批准文号
智通财经 · 10-19
ST人福(600079.SH):芦比前列酮软胶囊获得美国FDA批准文号
ST人福(600079)10月19日主力资金净买入3970.37万元
证券之星 · 10-19
ST人福(600079)10月19日主力资金净买入3970.37万元
ST人福(600079)10月16日主力资金净卖出4571.56万元
证券之星 · 10-16
ST人福(600079)10月16日主力资金净卖出4571.56万元
股市必读:ST人福新发布《关于舒更葡糖钠注射液获得英国药品和健康产品监管局(MHRA)上市许可的公告》
证券之星 · 10-15
股市必读:ST人福新发布《关于舒更葡糖钠注射液获得英国药品和健康产品监管局(MHRA)上市许可的公告》
ST人福(600079.SH):舒更葡糖钠注射液获得英国药品和健康产品监管局上市许可
智通财经 · 10-13
ST人福(600079.SH):舒更葡糖钠注射液获得英国药品和健康产品监管局上市许可
ST人福(600079)10月12日主力资金净买入1259.75万元
证券之星 · 10-12
ST人福(600079)10月12日主力资金净买入1259.75万元
股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》
证券之星 · 10-12
股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》
股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》
证券之星 · 10-09
股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》
ST人福(600079)披露2026年度向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺(二次修订稿)的公告,9月29日股价上涨0.11%
证券之星 · 09-29
ST人福(600079)披露2026年度向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺(二次修订稿)的公告,9月29日股价上涨0.11%
股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票申请文件的审核问询函的回复》
证券之星 · 09-28
股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票申请文件的审核问询函的回复》
ST人福(600079)披露2026年度向特定对象发行A股股票募集说明书(申报稿),9月23日股价上涨0.53%
证券之星 · 09-23
ST人福(600079)披露2026年度向特定对象发行A股股票募集说明书(申报稿),9月23日股价上涨0.53%
每周股票复盘:ST人福(600079)间苯三酚口崩片获注册证书
证券之星 · 09-13
每周股票复盘:ST人福(600079)间苯三酚口崩片获注册证书
ST人福(600079.SH)子公司间苯三酚口崩片获得药品注册证书
智通财经 · 09-11
ST人福(600079.SH)子公司间苯三酚口崩片获得药品注册证书
每周股票复盘:ST人福(600079)子公司普瑞巴林缓释片上市申请获受理
证券之星 · 09-06
每周股票复盘:ST人福(600079)子公司普瑞巴林缓释片上市申请获受理
ST人福(600079.SH):RFUS-949片进入II期临床试验研究
智通财经 · 09-03
ST人福(600079.SH):RFUS-949片进入II期临床试验研究
ST人福(600079)披露子公司普瑞巴林缓释片上市许可申请获受理,8月31日股价下跌0.27%
证券之星 · 08-31
ST人福(600079)披露子公司普瑞巴林缓释片上市许可申请获受理,8月31日股价下跌0.27%
ST人福(600079)2026年中报简析:净利润同比增长15.15%,盈利能力上升
证券之星 · 08-27
ST人福(600079)2026年中报简析:净利润同比增长15.15%,盈利能力上升
图解ST人福中报:第二季度单季净利润同比增长20.68%
证券之星 · 08-26
图解ST人福中报:第二季度单季净利润同比增长20.68%
ST人福(600079)披露2026年半年度报告,8月25日股价上涨0.95%
证券之星 · 08-25
ST人福(600079)披露2026年半年度报告,8月25日股价上涨0.95%
公司概况
公司名称:
人福医药集团股份公司
所属行业:
医药制造业
上市日期:
1997-06-06
主营业务:
人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、黄体酮原料药、祖卡木颗粒、复方木尼孜其颗粒。公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。
发行价格:
5.22
{"stockData":{"symbol":"600079","market":"SH","secType":"STK","nameCN":"ST人福","latestPrice":19.06,"timestamp":1792652400000,"preClose":19.49,"halted":0,"volume":13226300,"delay":0,"changeRate":-0.0221,"floatShares":1543000000,"shares":1632000000,"eps":1.2439,"marketStatus":"已收盘","change":-0.43,"latestTime":"10-22 15:00:00","open":19.45,"high":19.57,"low":19,"amount":254000000,"amplitude":0.0292,"askPrice":19.07,"askSize":287,"bidPrice":19.06,"bidSize":329,"shortable":0,"etf":0,"ttmEps":1.2439,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792719000000},"marketStatusCode":5,"adr":0,"adjPreClose":19.49,"symbolType":"stock","openAndCloseTimeList":[[1792632600000,1792639800000],[1792645200000,1792652400000]],"highLimit":20.46,"lowLimit":18.52,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":1632225965,"isCdr":false,"pbRate":1.61,"roa":"--","peRate":15.322775,"roe":"6.82%","epsLYR":1.14,"committee":-0.274934,"marketValue":31110000000,"turnoverRate":0.0086,"status":1,"floatMarketCap":29413000000},"requestUrl":"/m/hq/s/600079/wiki","defaultTab":"wiki","newsList":[{"id":"2677362618","title":"股市必读:ST人福新发布《关于芦比前列酮软胶囊获得美国FDA批准文号的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677362618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677362618?lang=zh_cn&edition=full","pubTime":"2026-10-21 01:17","pubTimestamp":1792516627,"startTime":"0","endTime":"0","summary":"截至2026年10月20日收盘,ST人福报收于19.55元,上涨1.3%,换手率0.89%,成交量13.71万手,成交额2.67亿元。当日关注点交易信息汇总:10月20日主力资金净流入1262.52万元,占总成交额4.73%。公司公告汇总:芦比前列酮软胶囊获美国FDA批准,获批用于成人慢性特发性便秘、阿片类药物诱导便秘及18岁及以上女性便秘型肠易激综合征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0012","600079","BK0185","BK0028","BK0239","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676394506","title":"ST人福(600079.SH):芦比前列酮软胶囊获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2676394506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676394506?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:49","pubTimestamp":1792396152,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司全资子公司人福普克药业(武汉)有限公司(简称“人福普克”)近日收到美国食品药品监督管理局(FDA)关于芦比前列酮软胶囊的批准文号。芦比前列酮软胶囊被批准用于治疗:(1)成人慢性特发性便秘(CIC);(2)用于伴有慢性非癌性疼痛的成人患者的阿片类药物诱导便秘(OIC),包括既往罹患癌症或癌症治疗相关慢性疼痛、且无需频繁(如每周)上调阿片类药物剂量的患者;(3)用于18岁及以上女性便秘型肠易激综合征(IBS‑C)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600079","BK4585","BK0096","BK0012","LABU","BK0239","BK0070","BK0188","BK0028","BK0185","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676055325","title":"ST人福(600079)10月19日主力资金净买入3970.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676055325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676055325?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:23","pubTimestamp":1792394590,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月19日收盘,ST人福报收于19.3元,上涨2.17%,换手率1.48%,成交量22.87万手,成交额4.42亿元。10月19日的资金流向数据方面,主力资金净流入3970.37万元,占总成交额8.99%,游资资金净流出3175.95万元,占总成交额7.19%,散户资金净流出794.42万元,占总成交额1.8%。ST人福主营业务:药品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900013080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","600079","BK0185","BK0028","BK0096","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675613125","title":"ST人福(600079)10月16日主力资金净卖出4571.56万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675613125","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675613125?lang=zh_cn&edition=full","pubTime":"2026-10-16 15:23","pubTimestamp":1792135434,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月16日收盘,ST人福报收于18.89元,下跌5.5%,换手率3.53%,成交量54.45万手,成交额10.73亿元。10月16日的资金流向数据方面,主力资金净流出4571.56万元,占总成交额4.26%,游资资金净流入50.28万元,占总成交额0.05%,散户资金净流入4521.28万元,占总成交额4.21%。ST人福主营业务:药品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600020782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0028","BK0188","BK0096","BK0070","BK0185","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675293113","title":"股市必读:ST人福新发布《关于舒更葡糖钠注射液获得英国药品和健康产品监管局(MHRA)上市许可的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675293113","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675293113?lang=zh_cn&edition=full","pubTime":"2026-10-15 01:14","pubTimestamp":1791998051,"startTime":"0","endTime":"0","summary":"公司公告汇总:舒更葡糖钠注射液获英国MHRA上市许可,有效期5年,2025年英国市场年销售额约8500万美元。公司公告汇总关于舒更葡糖钠注射液获得英国药品和健康产品监管局上市许可的公告人福医药集团股份公司控股子公司宜昌人福药业有限责任公司收到英国药品和健康产品监管局核准签发的舒更葡糖钠注射液上市许可批准信,获准在英国销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0012","600079","BK0185","BK0028","BK0239","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675331112","title":"ST人福(600079.SH):舒更葡糖钠注射液获得英国药品和健康产品监管局上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2675331112","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675331112?lang=zh_cn&edition=full","pubTime":"2026-10-13 16:06","pubTimestamp":1791878778,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,近日,公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”,公司持有其80%的股权)收到英国药品和健康产品监管局(MHRA)核准签发的舒更葡糖钠注射液的上市许可批准信。舒更葡糖钠注射液获得英国MHRA的上市许可,被批准的适应症为:在成人中拮抗罗库溴铵或维库溴铵诱导的神经肌肉阻滞;对于从出生至17岁的儿科患者,目前仅推荐用于常规拮抗罗库溴铵诱导的阻滞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0096","BK0028","600079","BK0188","IPOS","BK0070","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674822605","title":"ST人福(600079)10月12日主力资金净买入1259.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674822605","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674822605?lang=zh_cn&edition=full","pubTime":"2026-10-12 15:22","pubTimestamp":1791789767,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月12日收盘,ST人福报收于19.65元,上涨2.18%,换手率1.37%,成交量21.07万手,成交额4.13亿元。10月12日的资金流向数据方面,主力资金净流入1259.75万元,占总成交额3.05%,游资资金净流入422.43万元,占总成交额1.02%,散户资金净流出1682.18万元,占总成交额4.07%。ST人福主营业务:药品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200014531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0096","BK0028","600079","BK0188","BK0070","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674437338","title":"股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674437338","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674437338?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:27","pubTimestamp":1791739629,"startTime":"0","endTime":"0","summary":"公司公告汇总:控股子公司宜昌人福药业盐酸地尔硫片获美国FDA批准,规格覆盖30mg至120mg,用于治疗慢性稳定型心绞痛及冠状动脉痉挛引起的心绞痛。公司公告汇总关于盐酸地尔硫片获得美国FDA批准文号的公告人福医药集团股份公司控股子公司宜昌人福药业有限责任公司近日收到美国食品药品监督管理局关于盐酸地尔硫片的批准文号,ANDA批件号为220590,规格包括30mg、60mg、90mg和120mg。宜昌人福于2025年12月向美国FDA递交上市申请,累计研发投入约1200万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0096","BK0012","BK0185","BK0070","600079","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674500115","title":"股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674500115","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674500115?lang=zh_cn&edition=full","pubTime":"2026-10-09 01:03","pubTimestamp":1791478989,"startTime":"0","endTime":"0","summary":"公司公告汇总:宜昌人福盐酸地尔硫片获美国FDA批准,规格覆盖30mg至120mg,用于慢性稳定型心绞痛及冠状动脉痉挛引起的心绞痛。公司公告汇总关于盐酸地尔硫片获得美国FDA批准文号的公告人福医药集团股份公司控股子公司宜昌人福药业有限责任公司近日收到美国食品药品监督管理局关于盐酸地尔硫片的批准文号,ANDA批件号为220590,规格包括30mg、60mg、90mg和120mg。宜昌人福于2025年12月向美国FDA递交上市申请,累计研发投入约1,200万元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900001408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","600079","BK0185","BK0028","BK0096","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671021022","title":"ST人福(600079)披露2026年度向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺(二次修订稿)的公告,9月29日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671021022","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671021022?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:08","pubTimestamp":1790690901,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘,ST人福报收于18.83元,较前一交易日上涨0.11%,最新总市值为307.35亿元。该股当日开盘18.8元,最高19.0元,最低18.75元,成交额达1.15亿元,换手率为0.39%。近日,ST人福发布《关于公司向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺的公告》。控股股东及董事、高级管理人员也就填补回报措施作出相应承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900039756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0096","03188","82823","02846","BK0185","BK1610","399300","BK0012","02843","82843","BK0239","159982","BK0188","07233","02827","83130","03130","BK0028","BK0070","82846","BK1147","02823","83188","02822","82822"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670840951","title":"股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票申请文件的审核问询函的回复》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670840951","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670840951?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:24","pubTimestamp":1790529852,"startTime":"0","endTime":"0","summary":"大信会计师事务所关于人福医药集团股份公司向特定对象发行股票申请文件的审核问询函的回复公司拟募集资金总额300,000万元至350,000万元,用途同前;大信会计师事务所就募投项目必要性、产能消化风险、财务性投资认定等问题出具核查意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","600079","BK0028","BK0188","BK0185","BK0239","BK0096","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669056481","title":"ST人福(600079)披露2026年度向特定对象发行A股股票募集说明书(申报稿),9月23日股价上涨0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669056481","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669056481?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:13","pubTimestamp":1790172795,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘,ST人福报收于18.83元,较前一交易日上涨0.53%,最新总市值为307.35亿元。近日,人福医药集团股份公司披露《2026年度向特定对象发行A股股票募集说明书(申报稿)》。公告显示,公司拟向特定对象发行A股股票,募集资金总额不超过35亿元,用于创新药研发、两性健康及复杂制剂制造基地建设、数智化建设及补充流动资金。发行对象为公司控股股东招商生科,构成关联交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300040697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02827","BK0239","82846","BK0012","83130","159982","BK0070","BK0028","03130","BK0185","03188","600079","02846","399300","BK0096","BK0188","83188","BK1147","07233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667502008","title":"每周股票复盘:ST人福(600079)间苯三酚口崩片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667502008","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667502008?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:29","pubTimestamp":1789234149,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,ST人福报收于18.33元,较上周的18.73元下跌2.14%。本周,ST人福9月7日盘中最高价报18.99元。本周关注点来自公司公告汇总:间苯三酚口崩片获得药品注册证书,批准文号为国药准字H20265842。九珑人福已于2024年12月提交上市申请,累计投入约800万元。该产品获批后将丰富公司产品线,对公司产生积极影响,但未来销售受政策和市场因素影响存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","600079","BK0096","BK0070","BK0012","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544224","title":"ST人福(600079.SH)子公司间苯三酚口崩片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544224","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666544224?lang=zh_cn&edition=full","pubTime":"2026-09-11 15:44","pubTimestamp":1789112685,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司控股子公司武汉九珑人福药业有限责任公司近日收到国家药品监督管理局核准签发的间苯三酚口崩片的《药品注册证书》。间苯三酚口崩片用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛;急性痉挛性尿道、膀胱、肾绞痛;妇科痉挛性疼痛。该药品获批标志着子公司具备了在国内市场销售该产品的资格,将进一步丰富公司的产品线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ST人福(600079.SH)子公司间苯三酚口崩片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK0096","BK0070","600079","BK0012","BK0028","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936598","title":"每周股票复盘:ST人福(600079)子公司普瑞巴林缓释片上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936598","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665936598?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:44","pubTimestamp":1788630255,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,ST人福报收于18.73元,较上周的18.66元上涨0.38%。本周,ST人福9月2日盘中最高价报18.97元。本周关注点公司公告汇总:子公司普瑞巴林缓释片上市许可申请获国家药监局受理。公司公告汇总宜昌人福药业有限责任公司收到国家药品监督管理局签发的普瑞巴林缓释片药品注册上市许可《受理通知书》,该品种进入审评阶段。普瑞巴林缓释片适用于糖尿病周围神经病变相关神经病理性疼痛和带状疱疹后神经痛治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","600079","BK0028","BK0239","BK0070","BK0188","BK0012","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664279758","title":"ST人福(600079.SH):RFUS-949片进入II期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664279758","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664279758?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:12","pubTimestamp":1788423169,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”,公司持有其80%的股权)研发的RFUS-949片近日进入II期临床试验研究。试验名称:评价RFUS-949片用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂对照的疗效和安全性研究试验目的:评价RFUS-949片用于术后镇痛的疗效和安全性,探索RFUS-949片用于术后镇痛的用法用量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0070","600079","BK0185","BK0012","PSYK","IBBJ","BK0096","IBBQ","BMED","MDTX","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663507132","title":"ST人福(600079)披露子公司普瑞巴林缓释片上市许可申请获受理,8月31日股价下跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507132","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663507132?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:49","pubTimestamp":1788169769,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘,ST人福报收于18.61元,较前一交易日下跌0.27%,最新总市值为303.76亿元。该股当日开盘18.67元,最高18.71元,最低18.56元,成交额达1.56亿元,换手率为0.54%。近日,人福医药集团股份公司控股子公司宜昌人福药业有限责任公司收到国家药品监督管理局核准签发的普瑞巴林缓释片药品注册上市许可申请《受理通知书》,标志着该品种进入审评阶段。普瑞巴林缓释片用于治疗糖尿病周围神经病变相关神经病理性疼痛和带状疱疹后神经痛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100025225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0096","BK0028","600079","BK0188","BK0070","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074031","title":"ST人福(600079)2026年中报简析:净利润同比增长15.15%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074031","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662074031?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:02","pubTimestamp":1787781762,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期ST人福发布2026年中报。截至本报告期末,公司营业总收入120.61亿元,同比下降0.03%,归母净利润13.3亿元,同比上升15.15%。按单季度数据看,第二季度营业总收入59.59亿元,同比上升0.56%,第二季度归母净利润7.41亿元,同比上升20.68%。本报告期ST人福盈利能力上升,毛利率同比增幅4.09%,净利率同比增幅13.01%。去年的净利率为10.4%,算上全部成本后,公司产品或服务的附加值一般。本文数据来源于ST人福2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700010809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662768759","title":"图解ST人福中报:第二季度单季净利润同比增长20.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662768759","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662768759?lang=zh_cn&edition=full","pubTime":"2026-08-26 01:57","pubTimestamp":1787680650,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福2026年中报显示,上半年度公司主营收入120.61亿元,同比下降0.03%;归母净利润13.3亿元,同比上升15.15%;扣非净利润12.89亿元,同比上升14.02%;其中2026年第二季度,公司单季度主营收入59.59亿元,同比上升0.56%;单季度归母净利润7.41亿元,同比上升20.68%;单季度扣非净利润7.35亿元,同比上升22.67%;负债率39.66%,投资收益3992.94万元,财务费用2.11亿元,毛利率50.15%。财报数据概要请见下图:本文数据来源于ST人福2026年中报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600004334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662575383","title":"ST人福(600079)披露2026年半年度报告,8月25日股价上涨0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662575383","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662575383?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:29","pubTimestamp":1787668187,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,ST人福报收于18.02元,较前一交易日上涨0.95%,最新总市值为294.13亿元。该股当日开盘17.85元,最高18.02元,最低17.81元,成交额达9723.35万元,换手率为0.35%。近日,ST人福披露《2026年半年度报告》。公告显示,公司总资产为37,189,557,701.21元,较上年度末增长1.21%;归属于上市公司股东的净资产为19,308,987,553.37元,较上年度末增长2.09%。经营活动产生的现金流量净额为1,002,462,469.25元,同比增长16.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500051033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0070","600079","BK0239","BK0028","BK0012","BK0188","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792693623399,"stockEarnings":[{"period":"1week","weight":-0.0465},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.1393},{"period":"6month","weight":0.0529},{"period":"1year","weight":-0.0576},{"period":"ytd","weight":0.0814}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0744},{"period":"3month","weight":-0.0409},{"period":"6month","weight":-0.1034},{"period":"1year","weight":-0.0653},{"period":"ytd","weight":-0.0783}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"人福医药集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"78868人(较上一季度减少2.44%)","perCapita":"19566股","listingDate":"1997-06-06","address":"湖北省武汉市洪山区东湖高新区高新大道666号","registeredCapital":"163222万元","survey":" 人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、黄体酮原料药、祖卡木颗粒、复方木尼孜其颗粒。公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。","listedPrice":5.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST人福,600079,ST人福股票,ST人福股票老虎,ST人福股票老虎国际,ST人福行情,ST人福股票行情,ST人福股价,ST人福股市,ST人福股票价格,ST人福股票交易,ST人福股票购买,ST人福股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}